- Our Doctors
- Dr Sarah Smith
Dr Sarah Smith
MBBS, B Med Sci, MRCP, FRCR, Consultant Clinical Oncologist
Overview
Centers
Specialises in
Treatments
Dr Smith is a Consultant Clinical Oncologist specialising in anal, colorectal, ovarian and endometrial cancers.
She has a substantive consultant post at Cambridge University Hospitals NHS Foundation Trust where she is Clinical Lead for Radiotherapy.
Dr Smith’s specialist training took place in and around London, including UCLH, The Royal Marsden and Mount Vernon Hospitals prior to becoming a Consultant.
She is principle and co-investigator for multiple clinical trials with her areas of expertise and offers a comprehensive portfolio of cancer management including radiotherapy of all types including external beam radiotherapy, chemoradiation, SABR, vaginal vault brachytherapy and all forms of systemic therapy including chemotherapy, immunotherapy, targeted treatment and endocrine therapy.
Her private practice is based in Genesis Care Cambridge and Milton Keynes where patients can receive both radiotherapy and systemic therapies as well as complementary therapies to improve the patient journey.
She offers face to face appointments at Genesis Care Cambridge as well as video and telephone appointments across both the Cambridge and Milton Keynes sites.
Clinical interests
Accomplishments
Publications
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
- Nature Communications 16(1) (May 2925)
- In book: Radiological Anatomy for Radiation and Particle Therapy (March 2025)
- The Royal College of Radiologists Open (December 2023)
A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer
- Critical Reviews in Oncology/Hematology (January 2023)
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- The Lancet Oncology 21(3)(January 2020)
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer OPEN
- Nature.com/scientific reports (July 2019)
Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer
- European Journal of Radiology Open 6(11) (April 2019)
Principles of chemotherapy and radiotherapy
A pitfall of 18-fluorodeoxyglucose-PET in a patient with a tattoo
- The Lancet Oncology 8(12):1147-8 (January 2008)
Expertise and interests
Interests
- Rectal Cancer
- Anal Cancer
- Colon Cancer
Make a booking
We’re recognised by all private medical providers, including Bupa, AXA PPP, Aviva and Vitality. We’re always happy to answer any questions and concerns you may have.
Thank you for your enquiry.
We'll be in touch during our next working day (Monday to Friday, except for bank holidays)
Form submission error
There was an error submitting this form. Please refresh your screen and try again. If this error persists, please email contactus@genesiscare.co.uk for assistance.